Get the Stockscreener App
244.12
2.14%
5.12
After Hours:
244.12
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $244.12, with a volume of 1.68M.
It is up +2.14% in the last 24 hours and down -0.37% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
See More
Previous Close:
$239.00
Open:
$243.51
24h Volume:
1.68M
Relative Volume:
1.73
Market Cap:
$35.86B
Revenue:
$4.69B
Net Income/Loss:
$1.02B
P/E Ratio:
39.63
EPS:
6.16
Net Cash Flow:
$1.29B
1W Performance:
-0.84%
1M Performance:
-0.37%
6M Performance:
+23.27%
1Y Performance:
+65.09%
1-Day Range:
$240.24
$249.40
1-Week Range:
$238.74
$249.40
52-Week Range:
$132.24
$255.18
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
ResMed '2030 Strategy' aims for high-single-digit revenue growth. (NYSE:RMD) - Seeking Alpha
ResMed Unveils 2030 Strategy to Drive Growth, Profitability, and Shareholder Returns - Yahoo Finance
ResMed launches new patient-centric digital solutions for sleep apnea - Mass Device
RMDResMed Inc. Latest Stock News & Market Updates - StockTitan
ResMed launches new sleep apnea mask with tube-up design - Mass Device
UPDATE -- ResMed Unveils New Collection of Digital and Personalized Solutions designed to Improve Sleep Health - GlobeNewswire
Analyst lifts ResMed stock outlook, citing wearables and GLP-1 prospects - Investing.com
UPDATE -- ResMed Enhances CPAP Therapy with its First Fabric Mask, Designed to Make it Easier - The Bakersfield Californian
ResMed Enhances CPAP Therapy with its First Fabric Mask, - GlobeNewswire
ResMed Enhances CPAP Therapy with its First Fabric Mask, Designed to Make it Easier for People ... - The Hastings Tribune
ResMed Unveils New Collection of Digital and Personalized Solutions designed to Improve Sleep Health - The Bakersfield Californian
ResMed Unveils New Collection of Digital and Personalized Solutions designed to Improve Sleep Health - GlobeNewswire
ResMed Unveils New Collection of Digital and Personalized Solutions designed to Improve Sleep Health - StockTitan
Is ResMed Inc.'s (NYSE:RMD) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? - Yahoo Finance
ResMed's SWOT analysis: sleep apnea giant faces GLP-1 threat - Investing.com
Mackenzie Financial Corp Has $32 Million Holdings in ResMed Inc. (NYSE:RMD) - Defense World
ResMed Inc. (NYSE:RMD) Shares Bought by Mackenzie Financial Corp - MarketBeat
ResMed Inc. (NYSE:RMD) Shares Sold by Peloton Wealth Strategists - Defense World
ResMed Inc. (NYSE:RMD) Shares Sold by Susquehanna Portfolio Strategies LLC - Defense World
APG Asset Management N.V. Has $25.46 Million Holdings in ResMed Inc. (NYSE:RMD) - Defense World
Evergreen Capital Management LLC Purchases 378 Shares of ResMed Inc. (NYSE:RMD) - Defense World
ResMed Inc. (NYSE:RMD) Shares Sold by Susquehanna Portfolio Strategies LLC - MarketBeat
BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Grows Stake in ResMed Inc. (NYSE:RMD) - Defense World
ResMed Inc. stock falls Friday, underperforms market - MarketWatch
Baird R W Upgrades ResMed (NYSE:RMD) to Strong-Buy - MarketBeat
ResMed Inc. (NYSE:RMD) Shares Purchased by BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp - MarketBeat
Employees Retirement System of Texas Buys 41,900 Shares of ResMed Inc. (NYSE:RMD) - Defense World
Dundas Partners LLP Boosts Stock Position in ResMed Inc. (NYSE:RMD) - Defense World
Deerfield Management Company L.P. Series C Invests $1.45 Million in ResMed Inc. (NYSE:RMD) - Defense World
ResMed Inc. stock rises Thursday, outperforms market - MarketWatch
Deerfield Management Company L.P. Series C Makes New Investment in ResMed Inc. (NYSE:RMD) - MarketBeat
ResMed (NYSE:RMD) Eyes Growth with Board Expansion and Solid Earnings Despite Freight Cost Challenges - Yahoo Finance
ResMed Inc. stock falls Wednesday, underperforms market - MarketWatch
Zurich Insurance Group Ltd FI Cuts Stake in ResMed Inc. (NYSE:RMD) - Defense World
Pacer Advisors Inc. Raises Position in ResMed Inc. (NYSE:RMD) - Defense World
1832 Asset Management L.P. Trims Position in ResMed Inc. (NYSE:RMD) - Defense World
Marshall Wace LLP Takes Position in ResMed Inc. (NYSE:RMD) - Defense World
ResMed Inc.'s (NYSE:RMD) Stock Is Going Strong: Is the Market Following Fundamentals? - Simply Wall St
ResMed Inc. (NYSE:RMD) Shares Purchased by American Century Companies Inc. - Defense World
Zurich Insurance Group Ltd FI Has $77.51 Million Position in ResMed Inc. (NYSE:RMD) - MarketBeat
Baird Initiates Coverage of ResMed (RMD) with Outperform Recommendation - MSN
ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
Baird starts ResMed at outperform, cites growing sleep apnea market - MSN
Mount Yale Investment Advisors LLC Has $677,000 Holdings in ResMed Inc. (NYSE:RMD) - Defense World
Resources Management Corp CT ADV Trims Holdings in ResMed Inc. (NYSE:RMD) - Defense World
Ensign Peak Advisors Inc Increases Stock Holdings in ResMed Inc. (NYSE:RMD) - Defense World
ResMed (NYSE:RMD) Coverage Initiated at Robert W. Baird - MarketBeat
Mutual of America Capital Management LLC Lowers Holdings in ResMed Inc. (NYSE:RMD) - Defense World
Ensign Peak Advisors Inc Boosts Stock Holdings in ResMed Inc. (NYSE:RMD) - MarketBeat
ResMed Inc. (NYSE:RMD) Shares Sold by Federated Hermes Inc. - Defense World
ResMed Inc. stock rises Monday, outperforms market - MarketWatch
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.43%
3.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):